206 related articles for article (PubMed ID: 30472602)
1. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
[TBL] [Abstract][Full Text] [Related]
2. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
Löcken H; Clamor C; Müller K
J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and activity of BBI608 derivatives targeting on stem cells.
Zhou Q; Peng C; Du F; Zhou L; Shi Y; Du Y; Liu D; Sun W; Zhang M; Chen G
Eur J Med Chem; 2018 May; 151():39-50. PubMed ID: 29604543
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
Feng KR; Wang F; Shi XW; Tan YX; Zhao JY; Zhang JW; Li QH; Lin GQ; Gao D; Tian P
Eur J Med Chem; 2020 Sep; 201():112428. PubMed ID: 32603980
[TBL] [Abstract][Full Text] [Related]
5. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
Hubbard JM; Grothey A
Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
[TBL] [Abstract][Full Text] [Related]
6. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
Li X; Wei Y; Wei X
Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
[TBL] [Abstract][Full Text] [Related]
7. Identification of new shikonin derivatives as STAT3 inhibitors.
Qiu HY; Fu JY; Yang MK; Han HW; Wang PF; Zhang YH; Lin HY; Tang CY; Qi JL; Yang RW; Wang XM; Zhu HL; Yang YH
Biochem Pharmacol; 2017 Dec; 146():74-86. PubMed ID: 29066190
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
9. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
10. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
Li N; Ou J; Bao N; Chen C; Shi Z; Chen L; Sun J
Bioorg Chem; 2020 Nov; 104():104208. PubMed ID: 32919131
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
Hanafi M; Chen X; Neamati N
J Med Chem; 2021 Feb; 64(3):1626-1648. PubMed ID: 33506674
[TBL] [Abstract][Full Text] [Related]
13. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
Shao Z; Wang H; Ren H; Sun Y; Chen X
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570646
[TBL] [Abstract][Full Text] [Related]
14. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A
J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activities and SAR studies of substituted anthraquinones and 1,4-naphthoquinones.
Bhasin D; Etter JP; Chettiar SN; Mok M; Li PK
Bioorg Med Chem Lett; 2013 Dec; 23(24):6864-7. PubMed ID: 24176397
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3.
Wang X; He Q; Wu K; Guo T; Du X; Zhang H; Fang L; Zheng N; Zhang Q; Ye F
Eur J Med Chem; 2019 Oct; 179():218-232. PubMed ID: 31254923
[TBL] [Abstract][Full Text] [Related]
18. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
Bose M; Sanders A; Handa A; Vora A; Cardona MR; Brouwer C; Mukherjee P
Sci Rep; 2024 Feb; 14(1):3178. PubMed ID: 38326371
[TBL] [Abstract][Full Text] [Related]
19. N-Arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin.
Zhou Q; Zhu J; Chen J; Ji P; Qiao C
Bioorg Med Chem; 2018 Jan; 26(1):96-106. PubMed ID: 29174507
[TBL] [Abstract][Full Text] [Related]
20. Discovery, synthesis, and evaluation of small-molecule signal transducer and activator of transcription 3 inhibitors.
Shi ZB; Zhao D; Huang YY; Du Y; Cao XR; Gong ZN; Zhao R; Li JX
Chem Pharm Bull (Tokyo); 2012; 60(12):1574-80. PubMed ID: 23207637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]